Pliant Therapeutics, Inc. (PLRX)
0.6497
-0.01
(-1.59%)
USD |
NASDAQ |
Nov 18, 16:00
0.6497
0.00 (0.00%)
After-Hours: 20:00
Pliant Therapeutics Enterprise Value : -72.38M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | -72.38M |
| November 16, 2026 | -70.33M |
| November 13, 2026 | -70.10M |
| November 12, 2026 | -67.43M |
| November 11, 2026 | -65.10M |
| November 10, 2026 | -64.60M |
| November 09, 2026 | -63.74M |
| November 06, 2026 | -63.11M |
| November 05, 2026 | -62.73M |
| November 04, 2026 | -60.50M |
| November 03, 2026 | -59.95M |
| November 02, 2026 | -61.28M |
| October 30, 2026 | -60.06M |
| October 29, 2026 | -59.99M |
| October 28, 2026 | -58.15M |
| October 27, 2026 | -60.17M |
| October 26, 2026 | -60.63M |
| October 23, 2026 | -59.77M |
| October 22, 2026 | -59.66M |
| October 21, 2026 | -58.39M |
| October 20, 2026 | -56.74M |
| October 19, 2026 | -57.59M |
| October 16, 2026 | -57.52M |
| October 15, 2026 | -53.03M |
| October 14, 2026 | -58.51M |
| Date | Value |
|---|---|
| October 13, 2026 | -53.30M |
| October 12, 2026 | -52.18M |
| October 09, 2026 | -50.07M |
| October 08, 2026 | -51.31M |
| October 07, 2026 | -51.93M |
| October 06, 2026 | -49.45M |
| October 05, 2026 | -49.45M |
| October 02, 2026 | -49.14M |
| October 01, 2026 | -48.22M |
| September 30, 2026 | -46.36M |
| September 29, 2026 | -62.48M |
| September 28, 2026 | -62.48M |
| September 25, 2026 | -62.48M |
| September 24, 2026 | -58.77M |
| September 23, 2026 | -59.70M |
| September 22, 2026 | -58.77M |
| September 21, 2026 | -60.63M |
| September 18, 2026 | -60.63M |
| September 17, 2026 | -59.39M |
| September 16, 2026 | -63.10M |
| September 15, 2026 | -60.01M |
| September 14, 2026 | -58.15M |
| September 11, 2026 | -56.91M |
| September 10, 2026 | -59.39M |
| September 09, 2026 | -58.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -54.16M |
| CorMedix, Inc. | 160.77M |
| Eloxx Pharmaceuticals, Inc. | -8.293M |
| Breakthrough Chemistry, Inc. | -0.0298M |
| BioStem Technologies, Inc. | 17.64M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.38M |
| Total Expenses (Quarterly) | 24.38M |
| EPS Diluted (Quarterly) | -0.3935 |
| Earnings Yield | -225.1% |
| Normalized Earnings Yield | -217.56 |